SETTLEMENT AGREEMENTSettlement Agreement • November 9th, 2018 • Assertio Therapeutics, Inc • Pharmaceutical preparations • New Jersey
Contract Type FiledNovember 9th, 2018 Company Industry Jurisdiction
AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENTCommercialization Agreement • November 9th, 2018 • Assertio Therapeutics, Inc • Pharmaceutical preparations
Contract Type FiledNovember 9th, 2018 Company IndustryTHIS AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENT (this “Amendment No. 2”) is entered into as of August 29, 2018, by and among Assertio Therapeutics, Inc. (f/k/a Depomed, Inc.), a Delaware corporation (“Assertio”), Collegium Pharmaceutical, Inc., a Virginia corporation (“Collegium”), and Collegium NF, LLC, a Delaware limited liability company and wholly owned subsidiary of Collegium (“Newco”) and amends that certain Commercialization Agreement, dated as of December 4, 2017, as amended January 9, 2018 (the “Commercialization Agreement”), by and among Assertio, Collegium, and Newco. Each of Assertio, Collegium and Newco is referred to herein individually as a “party” and collectively as the “parties.” Defined terms used herein but not otherwise defined herein shall have the meaning ascribed to such terms in the Commercialization Agreement.